PROGRAMMED CELL DEATH 1 LIGAND 1

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 13:24:32 UTC 2023` Edited by `admin` on `Sat Dec 16 13:24:32 UTC 2023`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	L4766ELH5T
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PROGRAMMED CELL DEATH 1 LIGAND 1

Common Name

English

CD-274

Common Name

English

B7H1

Common Name

English

B7-H1

Common Name

English

PD-L1

Common Name

English

B7 HOMOLOG 1

Common Name

English

PROGRAMMED DEATH LIGAND 1

Common Name

English

CD274

Common Name

English

Code System Code Type Description

FDA UNII

L4766ELH5T

Created by admin on Sat Dec 16 13:24:32 UTC 2023 , Edited by admin on Sat Dec 16 13:24:32 UTC 2023

PRIMARY

WIKIPEDIA

PD-L1

Created by admin on Sat Dec 16 13:24:32 UTC 2023 , Edited by admin on Sat Dec 16 13:24:32 UTC 2023

PRIMARY

UNIPROT

Q9NZQ7

Created by admin on Sat Dec 16 13:24:32 UTC 2023 , Edited by admin on Sat Dec 16 13:24:32 UTC 2023

PRIMARY

From	To
1_22	1_96
1_137	1_191

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_17
N	1_174
N	1_182
N	1_201

Related Record Type Details


					A2B6R66VSJ

Nebratamig

LIGAND->TARGET

Amount:


					T8B91S15VF

INCB-086550

INHIBITOR -> TARGET

Amount:


					CSJ7UEQ4D9

GARIVULIMAB

INHIBITOR -> TARGET

Amount:


					V7XRB4BO26

BETIFISOLIMAB

INHIBITOR -> TARGET

Amount:


					V6W1OW12H2

FAZ-053

INHIBITOR -> TARGET

Amount:


					U3OZ7HX207

MANELIMAB

INHIBITOR -> TARGET

Amount:


					NW9K8C1JN3

BINTRAFUSP ALFA

INHIBITOR -> TARGET


					34DTV38QW5

Sotiburafusp Alfa

INHIBITOR -> TARGET

Interaction Type:

IN-VITRO

Amount:


					6C28YVJ79K

Cemavafusp

LIGAND->TARGET

Amount:


					TNM7KA4LB3

AB-001

INHIBITOR -> TARGET

Amount:


					ES1M06M6QH

ENVAFOLIMAB

INHIBITOR -> TARGET


					28X28X9OKV

DURVALUMAB

INHIBITOR -> TARGET

Interaction Type:

BINDING


					KXG2PJ551I

AVELUMAB

INHIBITOR -> TARGET

Comments:

Biacore

Interaction Type:

BINDING

Qualification:

Kd

Amount:


					F44C4N45HG

Danburstotug

INHIBITOR -> TARGET

Amount:


					20ZE3P16HV

OPUCOLIMAB

INHIBITOR -> TARGET


					E6OIF2QOI3

NM-21-1480

INHIBITOR -> TARGET

Amount:


					646MN6KQ16

CA-170

INHIBITOR -> TARGET

Amount:


					NR4MAD6PPB

LODAPOLIMAB

INHIBITOR -> TARGET


					82P4S8Q3FB

SOCAZOLIMAB

LIGAND->TARGET

Amount:


					6W6Z6G78V3

Ragistomig

INHIBITOR -> TARGET

Amount:


					90IQR2I6TR

SUGEMALIMAB

INHIBITOR -> TARGET


					PNW7GBB44P

COSIBELIMAB

INHIBITOR -> TARGET


					78V6PF4YBX

YPD-29B

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					3CX9U8V1CV

Enristomig

INHIBITOR -> TARGET

Amount:


					KX8KZX98PB

Umizortamig

LIGAND->TARGET

Amount:


					1XBY50W1OX

ADEBRELIMAB

INHIBITOR -> TARGET


					TLZ6R6973Z

BMS-936559

TARGET -> INHIBITOR


					603H2FWG4N

LY-3415244

INHIBITOR -> TARGET


					Q2GM754LLG

MAX-10181

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					52CMI0WC3Y

ATEZOLIZUMAB

INHIBITOR -> TARGET

Interaction Type:

BINDING


					GUY458P83P

TAGITANLIMAB

INHIBITOR -> TARGET

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL